Adults 18 to 70, any sex, with HIV Infection or Fatigue. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Goal Attainment Scale - Modified (GAS): Responder (Score of 3 - Goal Achieved) vs. Non-Responder (Score of 1 or 2 - Goal NOT Achieved)Primary· GAS Goal Responder vs. Goal Non-Responder will be assessed at Follow Up (3-6 months after the end of counseling)
Goal Attainment Scale - Prior to the beginning of counseling, the patient met with a member of the clinical team to develop an outcome GAS scale specific to their personal return to work goal. A goal was carefully established to be obtainable within the framework of 3-6 months, and to have observable anchors that could be scored on 3 outcome levels. A score of 3 indicates that they achieved their predetermined work goal and they were considered a "Responder" to the counseling. A score 2 indicates that some of the specific steps were taken towards the goal, but that it was not fully achieved. A
Group
Value
95% CI
Behavioral Activation Counseling
29
Supportive Counseling
9
Environmental Reward Observation Scale (EROS)Secondary· EROS will be measured at Follow-up (3-6 months after the end of counseling)
This 10-item scale developed to assess changes in activity level and is based on the premise of response-contingent reinforcement.
Score Range = 10 - 40 Higher scores suggest higher environmental reward.
Group
Value
95% CI
Behavioral Activation Counseling
27
± 7
Supportive Counseling
31
± 8
Behavioral Activation for Depression Scale (BADS)Secondary· BADS will be measured Follow-up (3-6 months after the end of counseling)
This 25 item scale total score is used to monitor change in Behavioral Activation (BA) protocols.
Score Range = 0 - 150 Higher scores suggest greater activation and less avoidance, as well as less social and work impairment.
Group
Value
95% CI
Behavioral Activation (BA) Counseling
99
± 28
Supportive Counseling (SC)
102
± 27
Sponsor's own description
The current study is a randomized clinical trial comparing Behavioral Activation counseling with supportive counseling for HIV+ participants presenting with clinically significant fatigue whose energy has improved with armodafinil, who have the goal of returning to work or vocational training but have not done so on their own. A second cohort of HIV+ participants without significant fatigue at baseline, but who also have the goal of returning to work, will also be randomized to either Behavioral Activation counseling or supportive counseling. In both cohorts, the primary outcome is level of success regarding an employment related goal.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06900829 — #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-i
· NA
· recruiting
NCT06908252 — MAPS PrEP Van Study
· Phase 4
· recruiting
NCT07042945 — MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)
· Phase 1
· recruiting
NCT06716450 — Multiplo Tp/HIV Self-Test
· NA
· recruiting
NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study
· recruiting
Other New York State Psychiatric Institute trials
Trials by the same sponsor.
NCT05416658 — Shared Decision Making for Antipsychotic Medications
· NA
· not yet recruiting
NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
· Phase 1, PHASE2
· not yet recruiting
NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual
· Phase 2
· not yet recruiting
NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD
· Phase 2
· suspended
NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis
· Phase 1
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
Last refreshed: 16 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02140775.